
==== Front
J Res Pharm Pract
J Res Pharm Pract
JRPP
J Res Pharm Pract
Journal of Research in Pharmacy Practice
2319-9644
2279-042X
Wolters Kluwer - Medknow India

JRPP-12-135
10.4103/jrpp.jrpp_25_24
Original Article
Evaluation of the Antimicrobial Resistance Pattern of Nosocomial Infections in Patients Hospitalized in Chamran Heart Educational, Medical, and Research Center of Isfahan
Dianatkhah Mehrnoush 12
Davoodi Zeinab Sadat 3
Soltani Rasool 1
Shafiee Fatemeh 4
Hosseini Alireza 5
1 Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran
2 Chamran Cardiovascular Medical and Research Hospital, Isfahan, Iran
3 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Pharmaceutical Biotechnology, Isfahan University of Medical Sciences, Isfahan, Iran
5 Department of Cardiac Surgery, Isfahan University of Medical Sciences, Isfahan, Iran
Address for correspondence: Dr. Zeinab Sadat Davoodi, E-mail: zdavoodi998@gmail.com
Oct-Dec 2023
08 8 2024
12 4 135140
08 4 2024
26 4 2024
05 5 2024
Copyright: © 2024 Journal of Research in Pharmacy Practice
2024
https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
ABSTRACT

Objective:

According to the importance of evaluating the antimicrobial resistance pattern in the management of nosocomial infections (NIs), we decided to investigate the prevalence of antimicrobial resistance in Chamran Heart Hospital.

Methods:

This retrospective cross-sectional observational study was performed for 6 months from February to July 2022 at Shahid Chamran Hospital of Isfahan, Iran. All hospitalized patients with any NIs were eligible for the study. Clinical specimens were obtained from patients with NIs. All specimens underwent microbial culture, and if bacterial growth developed, differential tests were performed. Antibiotic susceptibility testing also was performed per the standards of Clinical and Laboratory Standards Institute, 2022.

Findings:

Out of 201 examined samples, urinary infection (34.83%), pneumonia (27.86%), and sepsis (13.43%) were reported to be the most prevalent infections. Among Gram-negatives (76.12%), Citrobacter spp. (26.37%), Escherichia coli (24.87%), and Klebsiella spp. (11.44%) were the most common pathogens. About 54.9% of Citrobacter spp., 33.3% of E. coli, and 45.45% of Klebsiella spp. were resistant to carbapenems. About 1.88% and 15% of Citrobacter spp. were identified as pan-drug-resistant bacteria and extensively drug-resistant (XDR), respectively. In addition, 4.34% of Klebsiella spp. were identified as XDR. Among Gram-positives (23.88%), Enterococcus spp. (8.95%) was identified as the most common pathogen, and the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) was 11.11% and 61.11%, respectively.

Conclusion:

In our study, carbapenem-resistant Enterobacteriaceae accounts for about 50% of all NIs. Moreover, despite the low prevalence of MRSA, VRE was reported to be high in our center when compared with other studies.

KEYWORDS:

Antimicrobial resistance
nosocomial infection
prevalence
==== Body
pmcINTRODUCTION

Nosocomial infections (NIs) which complicate the usual course of hospitalization are a major therapeutic issue[123] and are defined as infections that occur within 48 h after hospitalization, 3 days after discharge, or 30 days after surgery.[4] The prevalence of NIs depends on various factors, and there are from 1.5% to 26.1% in different countries, and the prevalence of these infections in Iranian hospitals has been reported as 1.3%–10%.[4]

NIs can increase mortality, the duration of treatment, hospitalization costs, and antibiotic resistance, especially in developing countries.[13567] Several factors can be considered risk factors for NIs, such as suppression of the immune system, old age, increasing the duration of hospitalization (stay more than 8 days in the hospital), invasive procedures, hospitalization in the intensive care unit (ICU), and the use of broad-spectrum antibiotics.[348] As a result of the high use of antimicrobial agents, infectious pathogens have changed to resistant bacteria, and this has caused a great problem in the control, prevention, and treatment of NIs.[9] The World Health Organization has named antibiotic resistance as one of the three major threats to human health.[10] The rapid spread of antimicrobial resistance and its economic burden has become a serious public health issue around the world. According to the Centers for Disease Control and Prevention (CDC) report, more than 70% of bacteria causing NIs are resistant to at least one of the drugs used to treat them, and these infections are more lethal than antibiotic-sensitive strains of the same species.[9] Since the pattern of microbial resistance determines the strategy of experimental treatment and antibiotic prophylaxis, it seems necessary to examine the pattern of microbial resistance with short intervals in medical centers.[1112] Furthermore, based on the results of a systematic review study, monitoring the microbial prevalence pattern and microbial resistance of NI has a direct effect on reducing the rate of these infections.[7] Therefore, we decided to investigate the prevalence of NIs and the antibiotic resistance pattern at Shahid Chamran Heart Center in Isfahan, Iran.

METHODS

This retrospective cross-sectional observational study was performed during 6 months from February to July 2022 at Shahid Chamran Hospital of Isfahan, Iran, affiliated to Isfahan University of Medical Sciences. The study was approved by the ethical committee of Isfahan University of Medical Sciences with the ethics ID IR.MUI.RESEARCH.REC.1400.406.

All hospitalized patients with NIs were eligible for the study. Clinical specimens (blood, urine, sputum or bronchoalveolar lavage fluid, and wound secretion) were obtained from patients with NI according to CDC definition, using standard methods and aseptic technique by the trained personnel and were immediately transported to the hospital’s microbiology laboratory. All specimens underwent microbial culture, and if bacterial growth developed, differential tests were performed. Antibiotic susceptibility testing also was performed per the standards of the Clinical and Laboratory Standards Institute (CLSI, formerly National Committee for Clinical Laboratory Standards) guidelines (CLSI, 2022).[13] The resistant pattern of colistin and vancomycin was evaluated using the macrobroth dilution method, while other antibiotics were assessed by the disk diffusion method. Data analysis was done using Excel 2013.

RESULTS

During the study period, 201 patients with NIs were recognized, of whom 107 (53.23%) were male and 94 (46.77%) were female. Most NIs were observed in ICUs (n = 105, 52.23%), followed by the pediatrics and the internal ward (n = 16, 7.96% each). Urinary tract infection (UTI) (n = 70, 34.83%) and pneumonia (n = 56, 27.86%) showed the most frequency, followed by bloodstream infection (n = 27, 13.43%) and catheter site infection (n = 16, 7.96%).

Table 1 shows the frequency of each pathogen as the causative agent of each evaluated NIs. Among Gram-negatives, Citrobacter spp. (n = 53; 26.37%) and Escherichia coli (n = 50; 24.87%), and among Gram-positives, Enterococcus spp. and Staphylococcus spp. were the most frequently isolated nosocomial pathogens.

Table 1 Frequency of isolated pathogens from each nosocomial infection

Pathogen	Total	NI	
	
UTI, n (%)	Pneumonia, n (%)	BSI, n (%)	SSI, n (%)	Wound infection, n (%)	
Citrobacter spp.	53	11 (15.71)	21 (37.5)	6 (22.22)	3 (37.5)	5 (71.43)	
Escherichia coli	50	39 (55.71)	9 (16.07)	0	0	0	
Klebsiella spp.	23	12 (17.14)	6 (10.71)	3 (11.11)	0	0	
Enterococcus spp.	18	5 (7.14)	2 (3.57)	4 (14.81)	2 (25)	0	
CoNS	17	2 (2.86)	1 (1.78)	7 (25.39)	1 (12.5)	1 (14.28)	
Staphylococcus aureus	11	0	3 (5.36)	3 (11.11)	1 (12.5)	0	
Acinetobacter spp.	9	0	9 (16.07)	0	0	0	
Pseudomonas aeruginosa	8	0	2 (3.57)	1 (3.7)	0	1 (14.28)	
Enterobacter spp.	7	1 (1.43)	2 (3.57)	1 (3.7)	0	0	
Moraxella	3	0	1 (1.78)	1 (3.7)	0	0	
Micrococcus	2	0	0	1 (3.7)	1 (12.5)	0	
Total	201	70 (100)	56 (100)	27 (100)	8 (100)	7 (100)	
CoNS=Coagulase-negative staphylococcus, UTI=Urinary tract infection, BSI=Bloodstream infection, SSI=Surgical site infection, NI=Nosocomial infection

Table 2 shows the resistance pattern of bacteria isolated from each infection site. As shown among the Staphylococcus aureus, the prevalence of methicillin-resistant S. aureus (MRSA) was 11.11%. Moreover, among the Enterococcus species, the prevalence of Vancomycin-Resistant Enterococcus (VRE) was 61.11%, and none of the Staphylococcus species was sensitive to penicillin.

Table 2 Antibiotic resistance pattern of bacteria isolated from infection

Microorganism	Antibiotics	n	Susceptibility	
	
Sensitive, n (%)	Intermediate, n (%)	Resistant, n (%)	
Staphylococcus aureus	Penicillin	11	0	0	11 (100)	
Tetracycline	4	1 (25)	0	3 (75)	
Cefoxitin	9	8 (88.89) (MSSA)	0	1 (11.11) (MRSA)	
Clindamycin	10	6 (60)	0	4 (40)	
Co-trimoxazole	9	9 (100)	0	0	
Vancomycin	11	11 (100)	0	0	
CoNS	Penicillin	17	0	0	17 (100)	
Cefoxitin	17	9 (52.94)	0	8 (47.06)	
Clindamycin	16	3 (18.75)	0	13 (81.25)	
Co-trimoxazole	13	10 (76.92)	0	3 (23.1)	
Erythromycin	16	3 (18.75)	0	13 (81.25)	
Vancomycin	17	17 (100)	0	0	
Enterococcus spp.	Penicillin	18	8 (44.45)	0	10 (55.56)	
Ampicillin	18	8 (44.45)	0	10 (55.56)	
Ciprofloxacin	4	0	2 (50)	2 (50)	
Tetracycline	5	0	0	5 (100)	
Vancomycin	18	7 (38.8)	0	11 (61.11) (VRE)	
Citrobacter spp.	Cefotaxime	53	12 (22.64)	0	41 (77.36)	
Ceftriaxone	53	12 (22.64)	0	41 (77.36)	
Ciprofloxacin	38	12 (31.58)	6 (15.79)	20 (52.63)	
Co-trimoxazole	42	26 (61.9)	2 (4.76)	14 (33.3)	
Carbapenem	51	9 (17.65)	14 (27.45)	28 (54.9)	
Aminoglycoside	49	24 (48.98)	6 (12.24)	19 (38.77)	
Escherichia coli	Cefotaxime	50	13 (26)	0	37 (74)	
Ceftriaxone	50	13 (26)	0	37 (74)	
Ciprofloxacin	38	10 (26.31)	4 (10.53)	24 (63.16)	
Co-trimoxazole	39	14 (35.9)	0	25 (64.1)	
Carbapenem	45	18 (40)	12 (26.67)	15 (33.3)	
Aminoglycoside	48	35 (72.93)	0	13 (27.08)	
Klebsiella spp.	Cefotaxime	23	13 (56.52)	0	10 (43.48)	
Ceftriaxone	23	13 (56.52)	0	10 (43.48)	
Ciprofloxacin	19	10 (52.63)	0	9 (47.37)	
Co-trimoxazole	19	13 (68.42)	0	6 (31.58)	
Carbapenem	22	9 (40.9)	3 (13.64)	10 (45.45)	
Aminoglycoside	23	16 (69.56)	0	7 (30.43)	
Acinetobacter spp.	Ceftazidime	9	0	0	9 (100)	
Ciprofloxacin	9	0	0	9 (100)	
Co-trimoxazole	9	0	0	9 (100)	
Carbapenem	9	0	0	9 (100)	
Aminoglycoside	9	0	0	9 (100)	
Pseudomonas aeruginosa	Ceftazidime	6	4 (66.67)	2 (33.33)	0	
Ciprofloxacin	5	4 (80)	0	1 (20)	
Carbapenem	8	1 (12.5)	2 (25)	5 (62.5)	
Aminoglycoside	8	7 (87.5)	0	1 (12.5)	
Enterobacter spp.	Cefotaxime	7	3 (42.86)	0	4 (57.14)	
Ceftriaxone	7	3 (42.86)	0	4 (57.14)	
Ciprofloxacin	5	3 (60)	0	2 (40)	
Co-trimoxazole	7	5 (71.43)	0	2 (28.57)	
Carbapenem	7	1 (14.28)	2 (28.57)	4 (57.14)	
Aminoglycoside	7	4 (57.14)	0	3 (42.86)	
Moraxella spp.	Co-trimoxazole	3	3 (100)			
MSSA=Methicillin-sensitive staphylococcus aureus, MRSA=Methicillin-resistant staphylococcus aureus, VRE=Vancomycin-resistant enterococci

This table also shows the resistance pattern of Gram-negative bacteria isolated from the infection site. As shown, 54.9% of Citrobacter species were resistant to carbapenem, and among the carbapenem-resistant species, 7.14%, 28.57%, 35.71%, and 10.71% were sensitive to third-generation cephalosporins, aminoglycosides, co-trimoxazole, and fluoroquinolones, respectively. The most sensitivity among carbapenem-resistant Citrobacter species was reported to colistin and co-trimoxazole (100% and 35%, respectively). In addition, 16.98% of all Citrobacter species were resistant to all four groups of mentioned antibiotics (multidrug resistance [MDR]).

About 62.5% of Pseudomonas aeruginosa were resistant to carbapenem and the most sensitivity among this species was reported to aminoglycosides (87.5%).

Carbapenem resistance was reported in up to 45.45% of Klebsiella species. Among the carbapenem-resistant species, 60%, 40%, 40%, and 40% were sensitive to third-generation cephalosporins, aminoglycosides, fluoroquinolones, and co-trimoxazole, respectively.

According to Table 2, 33.33% of E. coli were resistant to carbapenem and among the carbapenem-resistant species, 6.67%, 40%, 13.33%, and 6.67% were sensitive to third-generation cephalosporins, aminoglycosides, fluoroquinolones, and co-trimoxazole, respectively.

Carbapenem resistance was reported in up to 57.14% of Enterobacter species. Among the carbapenem-resistant species, 50%, 50%, 25%, and 50% were sensitive to third-generation cephalosporins, aminoglycosides, fluoroquinolones, and co-trimoxazole, respectively.

About 80% of Acinetobacter species were reported as MDR and 20% as extensively drug-resistant (XDR) (resistant to all antibacterial categories including colistin).

DISCUSSION

In our study, the most prevalent NIs was UTI (34.83%), followed by pneumonia (27.86%). As could be expected, the highest prevalence of NIs occurred in the ICUs of the hospital.

Surprisingly, Citrobacter spp. was the most common pathogen in our study, which is not a common finding in similar studies. According to a study that was conducted from 2009 to 2014 in Taiwan, most of the patients who were infected with Citrobacter spp. infection was over 60 years old and had significant underlying diseases such as high blood pressure, diabetes, chronic kidney disease, and coronary artery disease.[14] These results are consistent with other studies.[15161718] Similarly, in our study, elderly patients who had underlying diseases were more susceptible to Citrobacter infection, and according to the results of our study, most of the patients who were infected with this infection had similar risk factors such as high blood pressure, diabetes mellitus, history of coronary artery bypass surgery, and kidney failure.

Based on our results, Citrobacter spp. was most sensitive to co-trimoxazole (61.9%) and most resistant to third-generation cephalosporins such as cefotaxime or ceftriaxone (77.36%). In a study of Korea in 2018 which evaluated patients from 2007 to 2017, 83.3%, 97%, and 100% of Citrobacter species were sensitive to co-trimoxazole, amikacin, and imipenem, respectively.[15] Similarly, in a study conducted in Taiwan, 72.2% of Citrobacter species were sensitive to co-trimoxazole,[14] and in Rajabi’s study which was conducted in Kerman, the sensitivity of Citrobacter to co-trimoxazole was 93.7%.[4] The high percentage of Citrobacter sensitivity to co-trimoxazole can be related to the less prevalent use of this antimicrobial agent in Iran.

Another considerable result of our study is the point that P. aeruginosa was more sensitive to ceftazidime in comparison with carbapenem, which can be a result of the high use of carbapenem antibiotics and less prevalent use of ceftazidime.

MRSA is one of the most prevalent pathogens causing NIs.[192021] In the present study, 11 cases of S. aureus were detected, and only one of them (11.11%) was MRSA, while in most studies, the number of MRSA species is reported to be around 50% of all S. aureus. For example, the prevalence of MRSA in the study which was conducted by Masoudifar et al. and Soltani et al. was reported to be 49% and 52.6%.[2223] In our study, 61.11% of Enterococcus spp. were resistant to vancomycin. Similarly, in Masoudifar’s study, 56.56% of Enterococcus spp. were resistant to vancomycin.[22]

In our study, the frequency of pan-drug-resistant and XDR Citrobacter was 1.88% and 15%, respectively, and the frequency of XDR Klebsiella was reported to be 4.34%. In Migliara’s study that was conducted in Italy, Acinetobacter baumannii and Klebsiella pneumoniae had the highest MDR rates with 100% and 94%, respectively, and about 47% of P. aeruginosa were also reported as MDR.[24] In Davoudi’s study, all cases of Acinetobacter were reported as MDR.[19] In our study, all cases of Acinetobacter were resistant to all tested antibiotics except colistin. Colistin sensitivity can be related to less and controlled use of this antimicrobial agent in Iran. The highest prevalence of NIs which caused by Acinetobacter spp. is related to the respiratory, especially in patients with mechanical ventilation.[25] To reduce the number of MDR microorganisms, it is necessary to choose antibiotics more carefully for the prophylaxis and treatment besides, the surgical environment should be aseptic, and wound management should be done properly.[26]

Among the limitations of the study, it can be said that in some cases, antibiotic treatment was started before the culture was sent to the laboratory, and as a result, many of those cultures were false negatives. Furthermore, due to the limitations of the hospital’s facilities, it was not possible to use the methods of determining antibiotic sensitivity with broth microdilution method and Minimum Inhibitory Concentration (MIC) determination to report more accurate results of antibiotic resistance. However, our study emphasizes the importance of correct antibiotic de-escalation according to the result of cultures to prevent the overuse of antibiotics and antimicrobial resistance.

In our study, carbapenem-resistant Enterobacteriaceae accounts for about 50% of all NIs. Moreover, despite the low prevalence of MRSA, VRE was reported to be high in our center when compared with other studies. So, our study emphasizes the importance of correct antibiotic de-escalation according to the result of cultures in order to prevent over use of antibiotics and antimicrobial resistance.

AUTHORS’ CONTRIBUTION

All authors contributed to the idea of the research, design of the study, data analysis, and manuscript preparation.

Financial support and sponsorship

This study was financially supported by the vice chancellery for research and technology of Isfahan University of Medical Sciences.

Conflicts of interest

There are no conflicts of interest.
==== Refs
REFERENCES

1 Izadi N Eshrati B Mehrabi Y Etemad K Hashemi-Nazari SS The national rate of intensive care units-acquired infections, one-year retrospective study in Iran BMC Public Health 2021 21 609 33781227
2 Duszynska W Rosenthal VD Szczesny A Zajaczkowska K Fulek M Tomaszewski J Device associated -health care associated infections monitoring, prevention and cost assessment at intensive care unit of University Hospital in Poland (2015-2017) BMC Infect Dis 2020 20 761 33066740
3 Askarian M Yadollahi M Assadian O Point prevalence and risk factors of hospital acquired infections in a cluster of university-affiliated hospitals in Shiraz, Iran J Infect Public Health 2012 5 169 76 22541264
4 Rajabi M Abdar ME Rafiei H Aflatoonia MR Abdar ZE Nosocomial infections and epidemiology of antibiotic resistance in teaching hospitals in South East of Iran Glob J Health Sci 2015 8 190 7 26383222
5 Flanders SA Collard HR Saint S Nosocomial pneumonia: State of the science Am J Infect Control 2006 34 84 93 16490612
6 Khan HA Baig FK Mehboob R Nosocomial infections: Epidemiology, prevention, control and surveillance Asian Pac J Trop Biomed [Internet 2017 7 478 82 Available from: https://www.sciencedirect.com/science/article/pii/S2221169116309509
7 Li Y Gong Z Lu Y Hu G Cai R Chen Z Impact of nosocomial infections surveillance on nosocomial infection rates: A systematic review Int J Surg 2017 42 164 9 28476543
8 Izadi N Eshrati B Etemad K Mehrabi Y Hashemi-Nazari SS Rate of the incidence of hospital-acquired infections in Iran based on the data of the national nosocomial infections surveillance New Microbes New Infect 2020 38 100768 33093962
9 Gastmeier P Geffers C Schwab F Fitzner J Obladen M Rüden H Development of a surveillance system for nosocomial infections: The component for neonatal intensive care units in Germany J Hosp Infect 2004 57 126 31 15183242
10 David N Gilbert RJ The 10 ×'20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020 Clin Infect Dis [Internet 2010 50 1081 3 Available from: https://academic.oup.com/cid/article-lookup/doi/10.1086/652237 20214473
11 Listed N authors Antimicrobial prophylaxis for surgery Treat Guidel Med Lett 2012 10 73 8 quiz 79-80 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22996382 [Last cited on 2021 Aug 04] 22996382
12 Bratzler DW Dellinger EP Olsen KM Perl TM Auwaerter PG Bolon MK , Clinical practice guidelines for antimicrobial prophylaxis in surgery Am J Health Syst Pharm 2013 70 195 283 23327981
13 CLSI M100-S24: Performance Standards for Antimicrobial Testing Susceptibility Wayne, PA Clin Lab Institute 2022 32th M100(January) 27 39
14 Liu LH Wang NY Wu AY Lin CC Lee CM Liu CP Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes J Microbiol Immunol Infect 2018 51 565 72 28711438
15 Lee R Choi SM Jo SJ Lee J Cho SY Kim SH , Clinical characteristics and antimicrobial susceptibility trends in Citrobacter bacteremia: An 11-year single-center experience Infect Chemother 2019 51 1 9 30941932
16 Lipsky BA Hook EW 3rd Smith AA Plorde JJ Citrobacter infections in humans: Experience at the Seattle Veterans administration medical center and a review of the literature Rev Infect Dis 1980 2 746 60 6763304
17 Shih CC Chen YC Chang SC Luh KT Hsieh WC Bacteremia due to Citrobacter species: Significance of primary intraabdominal infection Clin Infect Dis 1996 23 543 9 8879778
18 Mohanty S Singhal R Sood S Dhawan B Kapil A Das BK Citrobacter infections in a tertiary care hospital in Northern India J Infect 2007 54 58 64 16815552
19 Davoudi A Najafi N Alian S Tayebi A Ahangarkani F Rouhi S , Resistance pattern of antibiotics in patient underwent open heart surgery with nosocomial infection in North of Iran Glob J Health Sci 2015 8 288 97 26383221
20 Nelson MU Bizzarro MJ Baltimore RS Dembry LM Gallagher PG Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit in the decade following implementation of an active detection and isolation program J Clin Microbiol 2015 53 2492 501 26019206
21 Pacheco RL Lobo RD Oliveira MS Farina EF Santos CR Costa SF , Methicillin-resistant Staphylococcus aureus (MRSA) carriage in a dermatology unit Clinics (Sao Paulo) 2011 66 2071 7 22189732
22 Masoudifar M Gouya MM Pezeshki Z Eshrati B Afhami S Farzami MR , Health care-associated infections, including device-associated infections, and antimicrobial resistance in Iran: The national update for 2018 J Prev Med Hyg 2021 62 E943 9 35603257
23 Soltani R Khalili H Abdollahi A Rasoolinejad M Dashti-Khavidaki S Nosocomial Gram-positive antimicrobial susceptibility pattern at a referral teaching hospital in Tehran, Iran Future Microbiol 2012 7 903 10 22827310
24 Migliara G Di Paolo C Barbato D Baccolini V Salerno C Nardi A , Multimodal surveillance of healthcare associated infections in an intensive care unit of a large teaching hospital Ann Ig 2019 31 399 413 31304521
25 Forster DH Daschner FD Acinetobacter species as nosocomial pathogens Eur J Clin Microbiol Infect Dis 1998 17 73 7 9629969
26 Mulu W Kibru G Beyene G Damtie M Postoperative nosocomial infections and antimicrobial resistance pattern of bacteria isolates among patients admitted at Felege Hiwot referral hospital, Bahirdar, Ethiopia Ethiop J Health Sci 2012 22 7 18
